Genescience Pharmaceuticals Co. Ltd. has identified sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria (PKU).

Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) E542K mutant inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).

China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has disclosed heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Newrosetta Biosciences Co. Ltd. has described deuterated derivatives of AF-DX 116 acting as muscarinic M2 receptor antagonists reported to be useful for the treatment of myopia.

Scientists at Wuxi XDC (Shanghai) Co. Ltd. and Wuxi XDC Singapore Pvt Ltd. have divulged antibody-drug conjugates comprising antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of cancer.

Shenzhen Bay Laboratory has identified Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus and rheumatoid arthritis.

Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has described polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and gastric inhibitory polypeptide receptor (GIPR) agonists reported to be useful for the treatment of dyslipidemia, hepatic steatosis, metabolic syndrome, obesity and type 2 diabetes.

Amphista Therapeutics Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an F-Box only protein 22 (FBXO22)-binding moiety coupled to a transcriptional enhancer factor TEF (TEAD)-targeting moiety through a linker reported to be useful for the treatment of cancer.